About 10-15% of the EU population has chronic kidney disease (CKD) and this number is expected to increase in the next decades. This has major repercussions in Health costs. In fact, the cost of CKD, dialysis and renal transplantation could be as high as that for diabetes or cancer. Diabetes is the main cause of CKD in the EU: about 30% of the dialysis patients have diabetes. Also, we are facing a pandemic of overweight and obesity. Half of the adults in the EU has overweight or obesity. This is associated with a rise in hypertension and diabetes. Obese patients, particularly those with metabolic syndrome are at risk for CKD. Studying the links between Diabetes, Obesity and the renal damage is the core of the DOKI proposal. This may help preventing CKD and offering better treatments to renal patients.
European project
The study of the renal consequences of diabetes and obesity is a major goal of our group in the Instituto de Tecnologías Biomédicas (ITB) at the University of La Laguna (ULL), Canarias Islands, an outermost region of the EU.
We have experience in clinical and basic research in this particular area of knowledge. To move a step forward in our research line we created a network with two leading institutions: the Rigshospitalet at Copenhagen (Denmark) and the University of Oslo (Norway). This collaboration will improve our capacities, increase our knowledge and expand our vision in renal disease in obesity and diabetes.
About DOKI
Call: HORIZON-WIDERA-2021-ACCESS-03 (Twinning)
Topic: HORIZON-WIDERA-2021-ACCESS-03-01
Type of Action: HORIZON-CSA
Proposal number: 101079207
Proposal acronym: DOKI
